Studies have shown that Intelligent Complex Compound Gold III has the lowest known therapeutic dose in the world. It is effective at as low as 0.016 mg/kg of body weight, and virtually no side effects have been observed during its use. It is worth noting that the TGS Project has tested only 10 – 15% of the therapeutic potential of the Intelligent

Complex Compound Gold III in terms of application to various disease entities, the amount of effective therapeutic doses, and their routes of administration. 4 G4G – Projekt TGS It should also be emphasized that Intelligent Complex Compound Gold III is a fully synthetic, organic chemical compound that is much cheaper and faster to produce than the biological drugs currently dominating the pharmaceutical novelty market. The ability to purchase an innovative, highly effective, and less expensive drug is extremely important from the point of view of the actual payers – insurance companies and private and national health funds, many of which have been driven to the financial brink by the pandemic.

However, further implementation of the TGS Project will require another eight years of work and a substantial financial outlay of up to €150,000,000. Due to the high investment cost and the long construction time, the TGS Project has been divided into two-year investment cycles, during which investors will have the opportunity for both capital commitment and profit withdrawal. The TGS Project envisages the transformation of INWEX INTELLIGENT SOLUTIONS SA into a joint-stock public company listed initially on NC (New Connect) and ultimately on the main block of the Warsaw Stock Exchange (WSE).

The TGS Project assumes full control over the Project by the Invention Creators and Founders of INWEX INTELLIGENT SOLUTIONS SA. At the same time, a scenario of an early sale of a controlling stake to a Strategic Investor, e.g., an Industry Investor, is acceptable, provided that the interests of minority investors are secured. At the moment, taking into account only two therapeutic indications related to ulcerative colitis and cancer, the value of the TGS Project implemented by INWEX INTELLIGENT SOLUTIONS SA is estimated at €50,000,000. As the research, implementation, and legislative work progresses, this figure will increase to reach an eventual value of € 2,000,000,000 at the end of the Project..